Advertisement

Introduction to the Immune System

  • Scott McComb
  • Aude Thiriot
  • Bassel Akache
  • Lakshmi Krishnan
  • Felicity StarkEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2024)

Abstract

The immune system in a broad sense is a mechanism that allows a living organism to discriminate between “self” and “nonself.” Examples of immune systems occur in multicellular organisms as simple and ancient as sea sponges. In fact, complex multicellular life would be impossible without the ability to exclude external life from the internal environment. This introduction to the immune system will explore the cell types and soluble factors involved in immune reactions, as well as their location in the body during development and maintenance. Additionally, a description of the immunological events during an innate and adaptive immune reaction to an infection will be discussed, as well as a brief introduction to autoimmunity, cancer immunity, vaccines, and immunotherapies.

Key words

Immune system Immunity Vaccines Adjuvants Checkpoint CAR-T Adaptive immunity Innate immunity Inflammation 

References

  1. 1.
    Jenner E (1909) The three original publications on vaccination against smallpox. P.F. Collier & Son Company, New YorkGoogle Scholar
  2. 2.
    Cavaillon J-M (2011) The historical milestones in the understanding of leukocyte biology initiated by Elie Metchnikoff. J Leukoc Biol 90:413–424CrossRefGoogle Scholar
  3. 3.
    Kantha SS (1991) A centennial review; the 1890 tetanus antitoxin paper of von Behring and Kitasato and the related developments. Keio J Med 40:35–39CrossRefGoogle Scholar
  4. 4.
    Turk JL (1994) Almroth Wright—phagocytosis and opsonization. J R Soc Med 87:576–577PubMedPubMedCentralGoogle Scholar
  5. 5.
    Dreyer WJ, Bennett JC (1965) The molecular basis of antibody formation: a paradox. Proc Natl Acad Sci U S A 54:864–869CrossRefGoogle Scholar
  6. 6.
    Murphy K, Travers P, Walport M (2008) The humoral immune response. In: Janeway’s immunobiology, 7th edn. Garland Science, New YorkGoogle Scholar
  7. 7.
    Feola M, Merklin R, Cho S, Brockman SK (1977) The terminal pathway of the lymphatic system of the human heart. Ann Thorac Surg 24:531–536CrossRefGoogle Scholar
  8. 8.
    Medina E (2009) Neutrophil extracellular traps: a strategic tactic to defeat pathogens with potential consequences for the host. J Innate Immun 1:176–180CrossRefGoogle Scholar
  9. 9.
    Paust S, von Andrian UH (2011) Natural killer cell memory. Nat Immunol 12:500–508CrossRefGoogle Scholar
  10. 10.
    Leavy O (2014) Natural killer cells: RAG keeps natural killers fit. Nat Rev Immunol 14:716–717CrossRefGoogle Scholar
  11. 11.
    Karo JM, Sun JC (2015) Novel molecular mechanism for generating NK-cell fitness and memory. Eur J Immunol 45:1906–1915CrossRefGoogle Scholar
  12. 12.
    Rapp M, Lau CM, Adams NM et al (2017) Core-binding factor β and Runx transcription factors promote adaptive natural killer cell responses. Sci Immunol 2.  https://doi.org/10.1126/sciimmunol.aan3796CrossRefGoogle Scholar
  13. 13.
    Berzins SP, Smyth MJ, Baxter AG (2011) Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 11:131–142CrossRefGoogle Scholar
  14. 14.
    Bettelli E, Oukka M, Kuchroo VK (2007) T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8:345CrossRefGoogle Scholar
  15. 15.
    Dillman RO (2011) Cancer immunotherapy. Cancer Biother Radiopharm 26:1–64CrossRefGoogle Scholar
  16. 16.
    Waldmann TA (2017) Cytokines in cancer immunotherapy. Cold Spring Harb Perspect Biol.  https://doi.org/10.1101/cshperspect.a028472CrossRefGoogle Scholar
  17. 17.
    Simon JH, Jacobs LD, Campion M et al (1998) Magnetic resonance studies of intramuscular interferon β--1a for relapsing multiple sclerosis. Ann Neurol 43:79–87CrossRefGoogle Scholar
  18. 18.
    Asadullah K, Sterry W, Stephanek K et al (1998) IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 101:783–794CrossRefGoogle Scholar
  19. 19.
    Narula SK, Cutler D, Grint P (1998) Immunomodulation of Crohn’s disease by interleukin-10. Agents Actions Suppl 49:57–65PubMedGoogle Scholar
  20. 20.
    Vistnes M, Christensen G, Omland T (2010) Multiple cytokine biomarkers in heart failure. Expert Rev Mol Diagn 10:147–157CrossRefGoogle Scholar
  21. 21.
    Lacour S, Gautier J-C, Pallardy M, Roberts R (2005) Cytokines as potential biomarkers of liver toxicity. Cancer Biomark 1:29–39CrossRefGoogle Scholar
  22. 22.
    Marrack P, McKee AS, Munks MW (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9:287–293CrossRefGoogle Scholar
  23. 23.
    Garçon N, Di Pasquale A (2017) From discovery to licensure, the Adjuvant System story. Hum Vaccin Immunother 13:19–33CrossRefGoogle Scholar
  24. 24.
    Krieg AM (2012) CpG still rocks! Update on an accidental drug. Nucleic Acid Ther 22:77–89CrossRefGoogle Scholar
  25. 25.
    Alexander W (2016) The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge. P T 41:185PubMedPubMedCentralGoogle Scholar
  26. 26.
    Robert C, Ribas A, Wolchok JD et al (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109–1117CrossRefGoogle Scholar
  27. 27.
    Decker WK, da Silva RF, Sanabria MH et al (2017) Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models. Front Immunol 8:829CrossRefGoogle Scholar
  28. 28.
    Maus MV, June CH (2016) Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res 22:1875–1884CrossRefGoogle Scholar
  29. 29.
    Park JH, Rivière I, Gonen M et al (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378:449–459CrossRefGoogle Scholar
  30. 30.
    (1997) Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in the Gambia, Oman, and Thailand. J Infect Dis 175:S215–S227Google Scholar
  31. 31.
    Osterholm MT, Kelley NS, Manske JM et al (2013) The compelling need for game-changing influenza vaccines an analysis of the influenza vaccine enterprise and recommendations for the future, October 2012. CIDRAP, University of Minnesota, Minneapolis, MNGoogle Scholar
  32. 32.
    Vidal M, Chan DW, Gerstein M et al (2012) The human proteome - a scientific opportunity for transforming diagnostics, therapeutics, and healthcare. Clin Proteomics 9:6CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Scott McComb
    • 1
  • Aude Thiriot
    • 2
  • Bassel Akache
    • 1
  • Lakshmi Krishnan
    • 1
  • Felicity Stark
    • 1
    Email author
  1. 1.Human Health Therapeutics Research CentreNational Research Council of CanadaOttawaCanada
  2. 2.Division of Immunology, Department of Microbiology and ImmunobiologyHarvard Medical SchoolBostonUSA

Personalised recommendations